Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients.

With the advent new proteasome inhibitors (carfilzomib, ixazomib), new immune-modulatory drugs (pomalidomide), and new monoclonal antibodies (elotuzimab, daratumumab) as approved treatments for myeloma, the therapeutic landscape for this disease has changed. In this chapter, using a case-based approach, I will provide a personal guide of how I approach myeloma therapy in a transplant eligible patient in 2018.
Competing Interests: Conflict-of-interest disclosure: S.G. has received research funding and honoraria from Celgene, Sanofi, Amgen, Takeda, Novartis, Miltenyi, Pfizer, JAZZ, and Johnson & Johnson.
(© 2018 by The American Society of Hematology. All rights reserved.)